Trial Search Results

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Progen Pharmaceuticals

Stanford Investigator(s):

Intervention(s):

  • Drug: PI-88
  • Drug: placebo

Phase:

Phase 3

Eligibility


Key Inclusion Criteria:

   - Histologically-proven primary hepatocellular carcinoma with curative resection
   performed in the 4 - 6 weeks prior to randomisation.

   - ECOG performance status 0 to 2

   - Child Pugh classification A or B

Key Exclusion Criteria:

   - Any evidence of tumour metastasis or co-existing malignant disease

   - Any prior recurrence of HCC or any liver resection prior to the most recent procedure

   - History of prior HCC therapy

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kerry Hsieh
6507247245
Not Recruiting